Brendan Coffey

Insider stake now reaches 25.3 million shares held indirectly through Flat Capital AB, valued at $360 million as of transaction date.

Insider's $219 million private placement at $24.97 per share brings his aggregate stake to 11% ownership, with shares trading at a 14% premium just one day later.

Thompson's open-market purchase brings his direct stake to 4.1 million shares, representing 2.0% of outstanding equity amid a challenging one-year performance.

Rady's open-market purchase increases his indirect exposure to AAT's real estate portfolio spanning office, retail, and residential properties in high-barrier markets.

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

Barrenechea's purchase at $130.72 per share came after DKS stock fell 42% over 12 months, suggesting insider confidence at depressed valuations.

Rady's $2.3 million purchase brings his total beneficial ownership to $318.99 million, signaling confidence in the REIT's premium property portfolio.

Sakellaris acquired shares across two trading days at prices ranging from $21.86 to $23.00, boosting his direct stake to over 1 million shares.

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

Sutton's purchase follows a 14% stock decline over the past year, bringing his total beneficial stake to ~214,000 shares valued at $4.7 million.